Clinical translation in multiple myeloma: From bench to bedside

Seminars in Oncology

Volumn 40, Issue 5, 2013, Pages 549-553

  Laubach, Jacob ^a,b   Hideshima, Teru ^a,b   Richardson, Paul ^a,b   Anderson, Kenneth ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARMUSTINE; CASPASE 8; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VASCULOTROPIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; BONE REMODELING; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CORTICOSTEROID THERAPY; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; T LYMPHOCYTE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DESIGN; HUMANS; MICE; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; TREATMENT OUTCOME;

EID: 84886879230     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.07.009     Document Type: Article

References (57)

1. S.K. Kumar, S.V. Rajkumar, and A. Dispenzieri Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2008 2516 2520
2. C.P. Venner, J.M. Connors, and H.J. Sutherland Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months) Leuk Lymphoma 52 1 2011 34 41
3. J.H. Wright A case of multiple myeloma J Boston Soc Med Sci 4 8 1900 195 204
4. L.G. Longsworth, T. Shedlovsky, and D.A. Macinnes Electrophoretic patterns of normal and pathological human blood serum and plasma J Exp Med 70 4 1939 399 413
5. N. Blokhin, L. Larionov, N. Perevodchikova, L. Chebotareva, and N. Merkulova Clinical experiences with sarcolysin in neoplastic diseases Ann N Y Acad Sci 68 3 1958 1128 1132
6. D.E. Bergsagel, C.C. Sprague, C. Austin, and K.M. Griffith Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806) Cancer Chemother Rep 21 1962 87 99
7. B. Hoogstraten, P.R. Sheehe, and J. Cuttner Melphalan in multiple myeloma Blood 30 1 1967 74 83
8. D.R. Korst, G.O. Clifford, W.M. Fowler, J. Louis, J. Will, and H.E. Wilson Multiple myeloma. II. Analysis of cyclophosphamide therapy in 165 patients JAMA 189 1964 758 762
9. C.R. Tourtellotte, and M.K. Call Prolonged remission of myeloma with cyclophosphamide Arch Intern Med 113 1964 758 763
10. S.E. Salmon, R.K. Shadduck, and A. Shilling Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma Cancer Chemother Rep 51 1967 179 187
11. R.E. Maas A comparison of the effect of prednisone and a placebo in the treartment of multiple myeloma Cancer Chemother Rep 16 1962 257 259
12. R. Alexanian, M.A. Dimopoulos, K. Delasalle, and B. Barlogie Primary dexamethasone treatment of multiple myeloma Blood 80 1992 887 890
13. R. Alexanian, A. Haut, and A.U. Khan Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens JAMA 208 9 1969 1680 1685
14. B.J. Lee, G. Sahakian, B.D. Clarkson, and I.H. Krakhoff Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU Cancer 1974 33 1974 533 538
15. D. Samson, E. Gaminara, and A. Newland Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma Lancet ii 1989 882 885
16. Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials J Clin Oncol 16 1998 3832 3842
17. J. Blade, J. San Miguel, and M. Fontanillas Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients Hematol J 2 2001 272 278
18. A. Vacca, D. Ribatti, and L. Roncali Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503 508
19. A. Vacca, M. Di Loreto, and D. Ribatti Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44 Am J Hematol 50 1 1995 9 14
20. R.J. D'Amato, M.S. Loughman, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1994 4082 4085
21. H.M. Verheul, D. Panigrahy, J. Yuan, and R.J. D'Amato Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits Br J Cancer 79 1 1999 114 118
22. S. Singhal, J. Mehta, and R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 21 1999 1565 1571
23. T. Hideshima, D. Chauhan, and Y. Shima Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 9 2000 2943 2950
24. A. Palumbo, S. Bringhen, and T. Caravita Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 2006 825 831
25. T. Facon, J.Y. Mary, and C. Hulin Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 2007 1209 1218
26. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P.R. Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 2006 431 436
27. T. Hideshima, C. Mitsiades, G. Tonon, P.G. Richardson, and K.C. Anderson Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets Nat Rev Cancer 7 8 2007 585 598
28. D. Chauhan, Z. Tian, and B. Nicholson A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance Cancer Cell 22 3 2012 345 358
29. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Antimyeloma activity of heat shock protein-90 inhibition Blood 107 3 2006 1092 1100
30. P. Tassone, P. Neri, and D.R. Carrasco A clinically relevant SCID-hu in vivo model of human multiple myeloma Blood 106 2 2005 713 716
31. M. Chesi, G.M. Matthews, and V.M. Garbitt Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy Blood 120 2 2012 376 385
32. J.E. Delmore, G.C. Issa, and M.E. Lemieux BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 6 2011 904 917
33. Y.T. Tai, Y. Landesman, and C. Acharya CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications Leukemia 2013 Apr 16 [Epub ahead of print]
34. J. Delic, P. Masdehors, and S. Omura The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis Br J Cancer 77 7 1998 1103 1107
35. J. Chandra, I. Niemer, and J. Gilbreath Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes Blood 92 11 1998 4220 4229
36. T. Hideshima, C. Mitsiades, and M. Akiyama Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 2003 1530 1534
37. T. Hideshima, P. Richardson, and D. Chauhan The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 7 2001 3071 3076
38. R.Z. Orlowski, T.E. Stinchcombe, and B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 22 2002 4420 4427
39. P.G. Richardson, B. Barlogie, and J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 2609 2617
40. S. Jagannath, B. Barlogie, and J. Berenson A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 2 2004 165 172
41. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2005 2487 2498
42. P.K. Ha, N.E. Benoit, and R. Yochem A transcriptional progression model for head and neck cancer Clin Cancer Res 9 8 2003 3058 3064
43. N. Mitsiades, C.S. Mitsiades, and P.G. Richardson The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 6 2003 2377 2380
44. N. Mitsiades, C.S. Mitsiades, and V. Poulaki Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci U S A 99 22 2002 14374 14379
45. J.L. Harousseau, M. Attal, and H. Avet-Loiseau Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 30 2010 4621 4629
46. R.Z. Orlowski, A. Nagler, and P. Sonneveld Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 25 2007 3892 3901
47. J.F. San Miguel, R. Schlag, and N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 2008 906 917
48. M. Cavo, P. Tacchetti, and F. Patriarca Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 9758 2010 2075 2085
49. L. Rosinol, A. Oriol, and A.I. Teruel Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 8 2012 1589 1596
50. P. Sonneveld, I.G. Schmidt-Wolf, and B. van der Holt Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial J Clin Oncol 30 24 2012 2946 2955
51. P.G. Richardson, E. Weller, and S. Jagannath Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma J Clin Oncol 27 34 2009 5713 5719
52. P.G. Richardson, E. Weller, and S. Lonial Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 5 2010 679 686
53. D.E. Reece, G.P. Rodriguez, and C. Chen Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma J Clin Oncol 26 29 2008 4777 4783
54. S.K. Kumar, I. Flinn, and S.J. Noga Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study Leukemia 24 7 2010 1350 1356
55. P.G. Richardson, T. Hideshima, C. Mitsiades, and K.C. Anderson The emerging role of novel therapies for the treatment of relapsed myeloma J Natl Compr Cancer Network 5 2 2007 149 162
56. J.P. Laubach, A. Mahindra, and C.S. Mitsiades The use of novel agents in the treatment of relapsed and refractory multiple myeloma Leukemia 23 12 2009 2222 2232
57. S. Lonial, C.S. Mitsiades, and P.G. Richardson Treatment options for relapsed and refractory multiple myeloma Clin Cancer Res 17 6 2011 1264 1277